HC Wainwright Reaffirms “Buy” Rating for Valneva (NASDAQ:VALN)

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $26.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 243.46% from the stock’s previous close.

Valneva Price Performance

VALN stock traded up $0.11 during trading on Monday, hitting $7.57. 2,291 shares of the company’s stock traded hands, compared to its average volume of 10,114. Valneva has a 52 week low of $6.58 and a 52 week high of $15.29. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64. The business has a fifty day simple moving average of $7.89 and a 200 day simple moving average of $7.97. The stock has a market capitalization of $527.17 million, a price-to-earnings ratio of -18.46 and a beta of 2.20.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.77 by $0.12. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. The business had revenue of $35.56 million during the quarter, compared to analyst estimates of $95.80 million. As a group, research analysts expect that Valneva will post -0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. increased its stake in Valneva SE (NASDAQ:VALN) by 2.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the period. General American Investors Co. Inc. owned 0.51% of Valneva worth $2,831,000 as of its most recent SEC filing. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.